Curium Acquires Belgium's Abscint, Expanding HER2-Targeted Gallium-68 PET Oncology Radiopharmaceutical Diagnostics Pipeline
On August 10, 2026, radiopharmaceutical company Curium announced the completion of its acquisition of Abscint SA, a Belgian clinical-stage radiopharmaceutical company. The transaction grants Curium global development, manufacturing, and commercialization rights to ABS-011, further expanding its oncology PET radiopharmaceutical diagnostics portfolio. ABS-011 is an investigational gallium-68-labeled positron emission tomography (PET) radiopharmaceutical diagnostic tracer targeting human epidermal growth factor receptor 2 (HER2). HER2 is an important biological target in multiple cancers, including breast cancer and gastric cancer. Based on available information, ABS-011 is designed to enable whole-body quantitative imaging of HER2 expression, and following further clinical development and regulatory approval, has the potential to provide more comprehensive HER2 status information for patient characterization and clinical assessment.
2026-08-11
